FdaAdvisoryPanel

An expert panel will review Vivus' potential blockbuster drug Qnexa on Thursday, with the FDA making a decision in October. The FDA acknowledges the drug's effectiveness in cutting weight, but Qnexa will certainly draw scrutiny over its side effects.